Development and Evaluation of a Novel Drug Delivery System for Albendazole
Shaikh Karimunnisa1★, Pandhe Puja2, Kale Sangita1, Bothiraja Chellampillai2★ Corresponding author
- 1Department of Quality Assurance Techniques, Progressive Education Society’s Modern College of Pharmacy, Yamunanagar, Nigdi, Pune, Maharashtra, INDIA.
- 2Department of Pharmaceutics, Poona College of Pharmacy, Paud Road, Erandawane, Pune, Maharashtra, INDIA.
CORRESPONDENCE
Shaikh Karimunnisa
Department of Quality Assurance Techniques, Progressive Education Society’s Modern College of Pharmacy, Yamunanagar, Nigdi, Pune, Maharashtra, INDIA.
Received: 09-10-2017; Revised: 05-12-2017; Accepted: 06-12-2017.
Volume 52, Issue 3 · pp. 408–415 · PUBLISHED 2018 · DOI: 10.5530/ijper.52.3.47
ABSTRACT
Introduction: The main objective of the present study was to develop and evaluate long circulating pegylated niosomal formulation of albendazole (ABZ). It was hypothesized thatpegylated niosomes would increase the systemic residence time of albendazole in the treatment of echinococcosis thus obviating frequent doses of albendazole. Materials and methods: ABZ was received as a gift sample from SeQuent Scientific Limited, Mahad. Span 60 niosomes pegylated with Distearoyl-sn-glycero-3-phosphoethanolamine (DSPE-PEG procured from Sigma Aldrich) were prepared by ethanol injection method. They were evaluated for particle size, entrapment efficiency, zeta potential, in-vitro release and pharmacokinetic study. Results and discussion: The pegylated niosomes were 296.39±0.62 nm in size and spherical in nature. The nanosize of the niosomes will probably help in targeting the site of treatment of echinococcosis. Zeta potential, encapsulation efficiency and in-vitro release were 3.44 mV, 98.97% w/v and 92.93% w/v respectively. T90 of pegylated niosomes was found to be twice (1440.8 min) as that of free dug (720.2 min). Thus pegylated niosomes prolonged the release of albendazole. Hemolysis produced was less than 3%; thus niosomes proved safe for intravenous injection. Conclusion: Developed pegylated niosomes have potential in the treatment of echinococcosis and hydatid cysts. These niosomes will probably reduce the frequency of administration of albendazole
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Karimunnisa, S., Puja, P., Sangita, K., & Chellampillai, B. (2018). Development and Evaluation of a Novel Drug Delivery System for Albendazole. Indian Journal of Pharmaceutical Education and Research, 52(3), 408–415. https://doi.org/10.5530/ijper.52.3.47